Drug Search Results
More Filters [+]

Motexafin

Alternative Names: motexafin
Latest Update: 2024-04-04
Latest Update Note: PubMed Publication

Product Description

Mechanisms of Action: RR Inhibitor

Novel Mechanism: Yes

Modality: Small Molecule

Route of Administration: Intravenous

FDA Designation: None *

Approval Status: Not Approved

Approved Countries: None

Approved Indications: None

Known Adverse Events: None

Company: AbbVie
Company Location: NORTH CHICAGO IL 60064
Company CEO: Richard A. Gonzalez
Additonal Commercial Interests: None

Clinical Description

Map of Global Clinical Trials for Motexafin

Countries in Clinic:

Active Clinical Trial Count:

Highest Development Phases

Phase 3: Brain Cancer|Non-Small-Cell Lung Cancer

Phase 2: Lymphoma, B-Cell|Lymphocytic Chronic B-Cell Leukemia|Non-Small-Cell Lung Cancer|Breast Cancer|Chronic Lymphoid Leukemia|Melanoma|Adenocarcinoma|Multiple Myeloma|Brain Cancer|Brain Stem Cancer|Lymphoma, Non-Hodgkin|Glioblastoma|Glioma|Renal Cell Carcinoma|Gliosarcoma

Phase 1: Glioma|Astrocytoma|Colorectal Cancer|Myeloproliferative Disorders|Intestinal Cancer|Prostatic Diseases|Lung Cancer|Myelodysplastic-Myeloproliferative Diseases|Prostate Cancer|Breast Cancer|Multiple Myeloma|Intestinal Diseases|Glioblastoma|Oligodendroglioma|Lymphoma|Rectal Diseases|Head and Neck Cancer|Breast Diseases|Plasmacytoma|Leukemia, Plasma Cell|Hypopharyngeal Cancer|Gastrointestinal Cancer|Oropharyngeal Cancer|Laryngeal Cancer|Squamous Cell Carcinoma|Bronchogenic Carcinoma|Non-Small-Cell Lung Cancer

Trial

Phase

Trial Status

Disease

Primary Completion Date

Probability of Success

A6701QIBA

N/A

Unknown status

Prostate Cancer

2022-12-01

NCI-2009-01092

P2

Completed

Gliosarcoma|Glioblastoma

2011-02-16

NCI-2012-01829

P2

Completed

Glioma

2010-04-01

PCYC-0222

P2

Terminated

Lymphoma, B-Cell|Chronic Lymphoid Leukemia|Lymphocytic Chronic B-Cell Leukemia

2010-02-01

Recent News Events